Updates in the Pharmacotherapy of Endometriosis

Hugh Taylor, MD, differentiates endometriosis from other disorders causing pelvic pain and shares common risk factors for the disease.

Dr Hugh Taylor highlights the importance of early detection of disease and the use of imaging technology in the diagnosis of endometriosis.

An expert in reproductive endocrinology comments on the impact of endometriosis on a patient’s quality of life.

Robert N. Taylor, MD, PhD, reviews first- and second-line therapies for the treatment of endometriosis.

Dr Robert N. Taylor examines the use of GnRH receptor antagonists, including elagolix, for the management of endometriosis.

An expert reproductive endocrinologist comments on the patient selection of aromatase inhibitors and the role of selective estrogen receptor modulators (SERMs) for endometriosis treatment.

Robert N. Taylor, MD, PhD, discusses key findings from clinical trial data on the dosing, pain relief profile, and adverse events of elagolix for patients with endometriosis.

Dr Robert N. Taylor provides insight on emerging treatments and integrative therapies on the horizon with elagolix as well as real-world challenges using elagolix for endometriosis management.

An expert in reproductive endocrinology reviews endometriosis treatment options for various patient populations, including patients with infertility, endometriomas, deep endometriosis, and effects on nonreproductive organs.

Dr Hugh Taylor discusses his treatment approach for patients with presumed endometriosis.

Hugh Taylor, MD, provides insight on remaining gaps in care in the endometriosis treatment landscape.

An expert reproductive endocrinologist explores the future treatment landscape for patients with endometriosis.